PORTON DOWN, England, December 19 /PRNewswire/ -- Enigma Diagnostics, the life sciences company developing rapid molecular diagnostics systems, announces today the appointment of Professor Christopher Lowe as Non-executive Director.
Professor Lowe is Director of the Institute of Biotechnology at the University of Cambridge. He is a Fellow of the Royal Academy of Engineering, the Institute of Physics and the Royal Society of Chemistry.
Over the past 30 years, Prof. Lowe has focused on the development of pharmaceuticals, fine chemicals and diagnostics based on a highly inter- and multi-disciplinary approach. His approach combines aspects of biochemistry, microbiology, chemistry, electrochemistry, physics, electronics, medicine and chemical engineering, and from pure science to strategic applied science to the development of commercial applications.
He was recently awarded the title of "Most Entrepreneurial Scientist of the UK" by UKSEC and has co-founded seven spin-out companies, including ProMetic BioSciences Inc., Purely Proteins Ltd, Cambridge Sensors Ltd, Smart Holograms Ltd and Psynova Ltd.
Prof. Lowe has authored more than 300 publications, eight books and monographs, 60 patents and has formed many collaborations worldwide. He is an editorial board member of many academic journals, including Current Opinion in Biotechnology and the Journal of Nanotechnology, and a member of research council, grant-awarding and government committees.
John McKinley, Executive Chairman and CEO of Enigma Diagnostics, said: "I am very pleased that Chris has agreed to join Enigma's board. He is an outstanding scientist with exceptional credentials both in the academic and commercial circles. His proven ability to pull together complex scientific disciplines to achieve a desired goal will be invaluable to Enigma as we accelerate the development of our technology towards our core markets of clinical diagnostics, veterinary diagnostics, defence and security."
A photograph can be provided.
Notes to Editors:
About Enigma Diagnostics
Enigma Diagnostics Limited is a private UK based company developing the next generation of rapid diagnostic instrument platforms for the detection and identification of infectious organisms, such as bacteria and viruses, in clinical, environmental and biological samples.
Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based and point-of-care tests. The Company is targeting a number of multi-billion pound markets, core among which are the clinical, defence and homeland security, and veterinary markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of-care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will build an in-house sales and marketing capability to direct distribution of its bespoke products and partner with market leaders where global penetration of markets is required.
Enigma has an exclusive licence from the Defence Science Technology Laboratory to a portfolio of patents which represent over 15 years of UK Ministry of Defence funded research. Enigma's own R&D activities have added additional patents and design rights based upon its proprietary technologies to generate a portfolio of over 35-plus worldwide patents and patent applications dedicated to real-time PCR and wider rapid technologies. All of these patents are granted in a range of core territories such as US, EU and Japan with more extensive filing and grants across a number of other key territories.
Enigma DiagnosticsCONTACT: Contacts: Enigma Diagnostics, Deborah Cordingley, CorporateCommunications, deborah.cordingley@enigmadiagnostics.com; Dr Ian George,Business Development Director, ian.george@enigmadiagnostics.com,+44-1980-590131. Citigate Dewe Rogerson, Mark Swallow/Valerie Auffray/DavidDible, mark.swallow@citigatedr.co.uk, +44-207-638-9571
